Observational Study of NovoMix® 50 for Treatment of Type 2 Diabetics for 12 Months

A Prospective, Multicentre, Open Label, Un-controlled , Observational, 12-month Study in Subjects Using: NovoMix® 50 (Biphasic Insulin Aspart 50) for Treatment of Type 2 Diabetes Mellitus in Slovenia

This study is conducted in Europe. The aim of this observational study is to evaluate the blood glucose control when using NovoMix® 50 up to 12 months after initiation subjects with type 2 diabetes currently on a therapy with human biphasic insulin. An additional objective is also to observe the different regimes of starting and maintaining the treatment with NovoMix® 50 during one year.

Inclusion Criteria:

• Type 2 diabetes treated with biphasic human insulin with or without metformin
• Inadequate glycaemic control or is experiencing hypoglycaemic events or would, in the physician's opinion, benefit from treatment with NovoMix® 50

Exclusion Criteria:

• Subjects with diagnosed type 1 diabetes mellitus
• Subjects treated with short acting or intermediate acting human insulin or any insulin analogue
• Subjects who are unlikely to comply with study description, e.g. uncooperative attitude, inability to come for regular visits
• Subjects with a hypersensitivity to biphasic insulin aspart 50 (NovoMix® 50 )or to any of the excipients
• Women of childbearing potential, who are pregnant, breast-feeding or intend to become pregnant within next 12 months